@BantamPharma

At Bantam Pharmaceutical, we are developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors.

[@BantamPharma @bantampharma]

We are excited to be presenting new data in support of our lead drug BTM-3566 at #AACR2022. Read more here...https://t.co/pea6fre5JU

[@BantamPharma @bantampharma]

We’re delighted to share details of our data presented at #ASH21 on BTM-3566: https://t.co/cG6jKpIkAH

In models of #DLBCL, BTM-3566 treatment caused complete remission and resulted in complete tumor regression, with no subsequent tumor growth for the two weeks following therapy.

[@BantamPharma @bantampharma]

Later today Dr Adrian Schwarzer of @HannoverMh will present data on our lead candidate BTM-3566 at #ASH21.
Initially focused on #DLBCL, BTM-3566's unique anti-cancer MoA disrupts mitochondrial function in tumor cells to induce apoptosis (cell death).

#Oncology #HemOnc

[@BantamPharma @bantampharma]

Here we are at the first day of #ASH21! Looking forward to engaging with our colleagues in #hematology, and especially in #HemOnc and #TargetedTherapies.

Come and see us to learn more about our work in #MitochondrialDynamics and #CancerCare!

@ASH_hematology #ASH2021

[@BantamPharma @bantampharma]

⏰Save the date! On 13 December at #ASH21, Dr Adrian Schwarzer of @HannoverMh will be discussing new data on our lead candidate BTM-3566, in development for the treatment of #hematological malignancies including #DLBCL.

Learn more: https://t.co/EqMRNP9bfJ

See you there!

[@BantamPharma @bantampharma]

Not long now until the start of #ASH21! We’re so excited to be attending and sharing updates on our lead candidate BTM-3566.

For more details on our data visit: https://t.co/EqMRNP9bfJ

Follow us for more updates throughout the conference!

#Mitochondria #DLBCL #CancerCare

[ASH @ASH_hematology]

#ASH21 starts this week! How are you joining? Post a pic of your journey to the meeting, whether that’s boarding an airplane ✈️ or setting up your home office. 📚

Check out our journey to #ASH21: prepping the Georgia World Congress center for your arrival!

[Cancer Discovery @CD_AACR]

From the November issue: Medium-chain acyl CoA dehydrogenase protects #mitochondria from lipid #peroxidation in #glioblastoma. https://t.co/T804DZtMaJ.
Francesca Puca, @LyssiotisLab, Andrea Viale, @DraettaG and colleagues @MDAndersonNews @UMRogelCancer

[@BantamPharma @bantampharma]

We are excited to announce that data on our lead drug, BTM-3566 will be presented at the upcoming Annual Meeting of the American Society of Hematology. Read more here https://t.co/AzeWjnYLPS #ASH21

[@BantamPharma @bantampharma]

We are excited to announce that data on our lead drug, BTM-3566 will be presented at the upcoming Annual Meeting of the American Society of Hematology. Read more here https://t.co/AzeWjnYLPS #ASH21

[Gates Foundation @gatesfoundation]

This year, at the Bill & Melinda Gates Foundation, we are seeking out the tough questions. https://t.co/O5bGLlXInF

[@BantamPharma @bantampharma]

https://t.co/yQIuQ7wn8w

[@BantamPharma @bantampharma]

https://t.co/mzxpY1j2d4

[Susan Schaeffer @BiotechSusan]

This week in @BioCentury: Tumor kinetics modeling is informing dose and candidate selection, and identifying biomarkers. Some think it could yield better surrogates for OS. https://t.co/pohJQHkaLb

[Lisa Jarvis @lisamjarvis]

Can targeted protein degraders let drug hunters get at a whole new swath of targets? My deep dive: https://t.co/QpZyp8iBEi (image credit: Kymera Therapeutics)

[John Houston @JohnGHouston]

Great article summarizing where we are today in the protein degradation field #Arvinas #PROTACs https://t.co/NM7YRgxFRN

[Vipin Suri @VipinSuri4]

"Have compound, find target(s)" method using clickable covalent probes. Among other apps, these techniques are quite valuable in connecting pharmacology to targets especially as phenotypic screening becomes more widespread. More such methods, the better
https://t.co/jWhUZvSXIA

[Vipin Suri @VipinSuri4]

Cleverly designed affinity mass spec based search for PD-1 partners leads to identification of SLAM associated protein (SAP) as an inhibitor of PD-1 signaling through shielding of CD28 and other phosphotyrosine substrates from SHP-2 phosphatase. Nice study https://t.co/gehAOnc56O